Innovation Waves in Immuno-oncology Therapy Development - Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development
21 mars 2024 05h13 HE
|
Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Innovation Waves in Immuno-oncology Therapy Development" report has been added to ResearchAndMarkets.com's offering. Immuno-oncology (I-O)...
Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides
13 mars 2024 11h26 HE
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
Neuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research Nester
12 mars 2024 05h00 HE
|
Research Nester
New York, March 12, 2024 (GLOBE NEWSWIRE) -- The global neuroendocrine tumor treatment market size is slated to expand at ~12% CAGR between 2023 and 2035. The market is poised to garner a revenue of...
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
06 mars 2024 09h00 HE
|
GeoVax, Inc.
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Interleukin-2 (IL-2) Inhibitor Drug Pipeline Research Report 2024
05 mars 2024 03h30 HE
|
Research and Markets
Dublin, March 05, 2024 (GLOBE NEWSWIRE) -- The "Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides...
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
15 févr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it will host a conference call starting at 3...
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
14 févr. 2024 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that it has engaged IR Labs, Inc. (“irlabs”) to...
GeoVax Announces Multiple Patent Issuances and Allowances
13 févr. 2024 09h00 HE
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Global Immuno-oncology Market Projected at $ 396 Billion by 2034 with a 22.94% CAGR; Asia Pacific to Witness Fastest Growth
09 févr. 2024 07h42 HE
|
Research and Markets
Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering.The global immuno-oncology market size was estimated to be...
Global Cancer Immunotherapy Market to Reach $188.11 Billion by 2030, Propelled by Innovative Treatments and Rising Incidence Rates
05 févr. 2024 04h21 HE
|
Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report...